Cargando…

Organ-Sparing Strategies in Muscle-Invasive Bladder Cancer

Radical cystectomy (RC) is the treatment of choice and is strongly recommended for patients with pT2-4aN0M0 bladder cancer in both the European Association of Urology (EAU) and American Urological Association (AUA) muscle-invasive bladder cancer (MIBC) guidelines. RC is a challenging operation, with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Witjes, J Alfred, Feikema, Astrid A H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520819/ https://www.ncbi.nlm.nih.gov/pubmed/34675678 http://dx.doi.org/10.2147/CMAR.S294099

Ejemplares similares

Follow-up in non-muscle invasive bladder cancer: facts and future
por: Witjes, J. Alfred
Publicado: (2020)

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers
por: El-Taji, Omar M. S., et al.
Publicado: (2016)

Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer
por: Tholomier, Côme, et al.
Publicado: (2020)

AB007. Bladder-sparing treatments for muscle-invasive bladder cancer
por: Li, Shengwen, et al.
Publicado: (2017)

Bladder-sparing approaches for muscle invasive bladder cancer: a narrative review of current evidence and future perspectives
por: Fan, Xinxiang, et al.
Publicado: (2023)

Combined Modality Bladder-Sparing Therapy for Muscle-Invasive Bladder Cancer: How (Should) We Do It? A Narrative Review
por: Lemiński, Artur, et al.
Publicado: (2023)

Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer
por: Brummelhuis, Iris S. G., et al.
Publicado: (2021)

Adherence to the WCRF/AICR Cancer Prevention Recommendations and Risk of Recurrence in Non-muscle Invasive Bladder Cancer
por: van Zutphen, Moniek, et al.
Publicado: (2022)

Deceptive Muscle Invasive Bladder Cancer Recurrence With Benign Biopsy Foci After Bladder Sparing Treatment
por: Xu, Chuanliang, et al.
Publicado: (2015)

Will chemoradiation-based bladder-sparing therapy become a standard of care for muscle-invasive bladder cancer?
por: Koga, Fumitaka
Publicado: (2020)

Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
por: van Hoogstraten, Lisa M.C., et al.
Publicado: (2022)

Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial
por: Galsky, Matthew D., et al.
Publicado: (2023)

Low adherence to recommended use of neoadjuvant chemotherapy for muscle-invasive bladder cancer
por: van Hoogstraten, Lisa M. C., et al.
Publicado: (2023)

Limited Changes in Lifestyle Behaviours after Non-Muscle Invasive Bladder Cancer Diagnosis
por: Beeren, Ivy, et al.
Publicado: (2022)

LINC00857 expression predicts and mediates the response to platinum‐based chemotherapy in muscle‐invasive bladder cancer
por: Dudek, Aleksandra M., et al.
Publicado: (2018)

Bladder Preservation for Muscle Invasive Bladder Cancer
por: Mirza, Arafat, et al.
Publicado: (2016)

Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
por: Lammers, Rianne J. M., et al.
Publicado: (2015)

Real-world retrospective study of immune checkpoint inhibitors in combination with radiotherapy or chemoradiotherapy as a bladder-sparing treatment strategy for muscle-invasive bladder urothelial cancer
por: Xu, Chao, et al.
Publicado: (2023)

Neoadjuvant Chemotherapy–Guided Bladder-Sparing Treatment for Muscle-Invasive Bladder Cancer: Results of a Pilot Phase II Study
por: Shi, Hongzhe, et al.
Publicado: (2021)

Body mass index and waist circumference in relation to risk of recurrence and progression after non‐muscle invasive bladder cancer
por: van Zutphen, Moniek, et al.
Publicado: (2023)

Perpetual role of brachytherapy in organ-sparing treatment for bladder cancer: a historical review
por: der Steen-Banasik, Elzbieta Van, et al.
Publicado: (2020)

Incidence and outcome of salvage cystectomy after bladder sparing therapy for muscle invasive bladder cancer: a systematic review and meta-analysis
por: Schuettfort, Victor M., et al.
Publicado: (2020)

Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer
por: Ripping, Theodora M., et al.
Publicado: (2021)

Clinical Validation of a Urine Test (Uromonitor-V2(®)) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients
por: Sieverink, Caroline A., et al.
Publicado: (2020)

Double-Blind, Randomized, Placebo-controlled Studies Evaluating Apaziquone (E09, Qapzola™) Intravesical Instillation Post Transurethral Resection of Bladder Tumors for the Treatment of Low-risk Non-Muscle Invasive Bladder Cancer
por: Karsh, Lawrence, et al.
Publicado: (2018)

Muscle Invasive Bladder Cancer: From Diagnosis to Survivorship
por: Mohamed, N. E., et al.
Publicado: (2012)

Predictors of Outcome of Non–Muscle-Invasive and Muscle-Invasive Bladder Cancer
por: Youssef, Ramy F., et al.
Publicado: (2011)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

Neoadjuvant Immunotherapy for Muscle-Invasive Bladder Cancer
por: Peyrottes, Arthur, et al.
Publicado: (2021)

Preservation of Erectile and Ejaculatory Functions After Tetramodal Bladder-Sparing Therapy Incorporating Consolidative Partial Cystectomy Against Muscle Invasive Bladder Cancer
por: Uchida, Yusuke, et al.
Publicado: (2023)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
por: Tan, Wei Shen, et al.
Publicado: (2023)

Circulating Tumour DNA in Muscle-Invasive Bladder Cancer
por: Tan, Melissa P., et al.
Publicado: (2018)

Where are we with bladder preservation for muscle-invasive bladder cancer in 2017?
por: Smelser, Woodson Wade, et al.
Publicado: (2017)

Editorial comment: bladder preservation as a treatment strategy in muscle-invasive bladder cancer
por: Ajib, Khaled, et al.
Publicado: (2018)

Perioperative therapy in muscle invasive bladder cancer
por: Chatterjee, Ambarish, et al.
Publicado: (2021)

DPPG(2)-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer
por: van Valenberg, F Johannes P, et al.
Publicado: (2021)

Bladder preservation in muscle-invasive bladder cancer: a comprehensive review
por: Hamad, Judy, et al.
Publicado: (2020)

Downstaging of TURBT-Based Muscle-Invasive Bladder Cancer by Radical Cystectomy Predicts Better Survival
por: van Dijk, P. R., et al.
Publicado: (2011)

Applications of Exosomes in Diagnosing Muscle Invasive Bladder Cancer
por: Walker, Jillian Marie, et al.
Publicado: (2022)

Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
por: Hendricksen, Kees, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_41ocoudol15t5otib7i372e81o